<DOC>
	<DOCNO>NCT00376519</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy , fludarabine cyclophosphamide , total-body irradiation donor umbilical cord blood stem cell transplant help stop growth cancer abnormal cell prepare patient 's bone marrow stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . The donated stem cell may replace patient 's immune cell help destroy remain cancer abnormal cell ( graft-versus-tumor effect ) . Giving infusion donor 's T-regulatory cell transplant may help increase effect . Sometimes transplanted cell donor make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This phase I trial study side effect best dose umbilical cord blood T-regulatory cell infusion follow donor umbilical cord blood transplant treat patient high-risk leukemia hematologic disease .</brief_summary>
	<brief_title>Umbilical Cord Blood T-Regulatory Cell Infusion Followed Donor Umbilical Cord Blood Transplant Treating Patients With High-Risk Leukemia Other Hematologic Diseases</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose umbilical cord blood ( UCB ) -derived CD4- CD25-positive T-regulatory ( Treg ) cell infusion follow double unrelated donor UCB transplantation patient high-risk leukemia hematologic disease . Secondary - Determine speed neutrophil platelet recovery day 42 patient . - Determine incidence `` double chimerism '' ( e.g. , engraftment UCB unit ) day 21 patient . - Determine risk severe grade III-IV acute graft-versus-host disease ( GVHD ) day 100 patient . - Determine risk chronic GVHD 1 year post transplantation patient . - Determine probability survival 100 day 1 year post transplantation patient . OUTLINE : This open-label , dose-escalation study CD4- CD25-positive umbilical cord blood ( UCB ) -derived T-regulatory cell ( Treg ) . - Preparative therapy : Patients receive fludarabine phosphate intravenously ( IV ) 1 hour day -9 -7 cyclophosphamide IV 2 hour day -8 -7 ( 1 hour fludarabine infusion ) . Patients undergo total-body irradiation ( TBI ) twice daily day -5 -2 . - UCB-derived Treg infusion : Patients receive UCB-derived Treg cell IV day -1 . - Double unrelated donor UCB transplantation : Patients undergo double unrelated donor UCB transplantation IV infusion day 0 . - Graft-versus-host disease ( GVHD ) prophylaxis : Patients receive cyclosporine IV 2 hour orally 2 3 time daily begin day -3 continue day 100 , follow taper day 180 , absence GVHD . Patients also receive mycophenolate mofetil ( MMF ) orally IV twice daily day -3 30 7 day engraftment , whichever later , absence acute GVHD* . If donor engraftment occurs , MMF may continue discretion attend physician . NOTE : *If patient acute GVHD require systemic therapy , MMF may stop 7 day GVHD control ( e.g. , resolution skin rash , vomit , diarrhea ) . Cohorts 3-6 patient receive escalate dos UCB-derived Treg cell maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience nonhematologic dose-limiting toxicity within 48 hour Treg cell infusion . At least 6 patient treated MTD .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patient Donor Demographic Criteria Patient must 1845 year age . Patients must three partially HLA match UCB unit . Units identify HSC source must HLA match 46 HLA A B ( low intermediate resolution ) DRB1 ( high resolution ) , unit must HLA match 46 HLA A , B , DRB1 antigens . Total cryopreserved HSC graft cell dose must &gt; 2.5 x 107 nucleated cell per kilogram recipient body weight . Also , two umbilical cord blood ( UCB ) unit must ABOmatched . The UCB unit identify Treg source must HLA match 46 HLA antigen patient ( without HLA ABO match criterion UCB HSC source ) . Disease Criteria Patients must hematological malignancy list : Acute myelogenous leukemia : high risk CR1 ( evidence precede myelodysplastic syndrome ( MDS ) , high risk cytogenetics associated MDS complex karyotype , &gt; 2 cycle obtain complete remission ( CR ) ; second great CR . Must remission morphology ( &lt; 5 % blast within normocellular marrow ) . Acute lymphocytic leukemia : high risk CR1 evidence high risk cytogenetics [ ( 9 ; 22 ) , ( 1:19 ) , ( 4 ; 11 ) MLL rearrangement ] &gt; 1 cycle obtain CR ; second great CR . Chronic myelogenous leukemia resistant imatinib therapy Myelodysplasia ( MDS ) IPSS Int2 High risk ( i.e . RAEB , RAEBt ) refractory anemia severe pancytopenia high risk cytogenetics . Blasts must &lt; 10 % representative bone marrow aspirate morphology ( otherwise induction chemotherapy achieve &lt; 10 % blast require pretransplant ) . Advanced myelofibrosis Chronic lymphocytic leukemia/small lymphocytic lymphoma ( CLL/SLL ) , marginal zone Bcell lymphoma follicular lymphoma progress least two prior therapy . Patients bulky disease ( nodal mass great 5 cm ) consider debulking chemotherapy transplant . Lymphoplasmacytic lymphoma , mantlecell lymphoma , prolymphocytic leukemia eligible initial therapy CR1+ PR1+ . Large cell nonHodgkins lymphoma ( NHL ) &gt; CR2/ &gt; PR2 . Patients CR2/PR2 initial short remission ( &lt; 6 month ) eligible . Lymphoblastic lymphoma , Burkitt 's lymphoma , highgrade NHL initial therapy stage III/IV CR1/PR1 progression stage I/II &lt; 1 year . Multiple myeloma beyond PR2 . Patients chromosome 13 abnormality , first response last less 6 month , Î²2 microglobulin &gt; 3 mg/L , may consider protocol initial therapy . Recipients Karnofsky score &gt; 80 % acceptable organ function ie creatinine &lt; 2.0 , bilirubin , AST/ALT , ALP &lt; 2 x normal , pulmonary function &gt; 50 % normal , leave ventricular ejection fraction &gt; 45 % . Note : All patient creatinine &gt; 1.2 history renal dysfunction must creatinine clearance ( must &gt; 40 ml/min eligible ) . Recipients sign informed consent approve Committee Use Human Subjects University Minnesota . Pregnant breastfeed Evidence HIV infection know HIV positive serology Current active infection Available HLA match sibling donor . CML active blast crisis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>chronic myelogenous leukemia</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>follicular lymphoma</keyword>
	<keyword>mantle cell lymphoma</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>secondary myelofibrosis</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>marginal zone lymphoma</keyword>
	<keyword>diffuse large cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>lymphoblastic lymphoma</keyword>
	<keyword>immunoblastic large cell lymphoma</keyword>
	<keyword>multiple myeloma</keyword>
</DOC>